SIMRIS_B has reported a significant drop in net revenue, which decreased by 44% year-over-year. Despite improvements in EBITDA and EBIT, the company is grappling with negative equity and cash flow issues. As part of its strategic shift towards biotechnology, SIMRIS_B is actively seeking new capital to address its urgent liquidity needs.
The company is also pursuing asset divestment opportunities while aiming to expand its presence in the antibody-drug conjugate (ADC) market. This transition highlights the importance of sustainable growth and innovation within the biotech sector, which is increasingly critical in today’s research landscape.
For those interested in funding opportunities in the biotechnology field, various resources are available, including government grants and private investment options. Stakeholders are encouraged to explore these avenues to support similar transitions in the industry.
For further details, please refer to the original document: Simris Group AB Class B [SIMRIS_B] Interim report — Feb. 28 2026.